LP101502-5
Interferon.beta 1b Ab
Active
Description
Highly elevated levels of neutralizing antibodies (NAbs >1:100) to interferon-beta used as therapy in patients with Multiple Sclerosis have been reported to correlate with predictable loss of interferon-beta bioactivity. In patients with elevated NAb levels from >1:20 to <1:100, interferon-beta bioactivity may still be present, but does not necessarily correlate to the exact NAb titer, and continued patient monitoring may be warranted. There is no apparent loss of interferon-beta bioactivity in patients who test positive in the binding antibody assay, but
negative for NAbs; however, continued patient monitoring may also be warranted in this instance as well.
Source: Quest Diagnostics Inc.,
Interferon-beta 1a (IFNB-1a) Antibody
Basic Part Properties
- Part Name
- Interferon.beta 1b Ab
- Part Display Name
- Interferon.beta 1b Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2010-08-27
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| fr-FR | French (France) | Interféron bêta 1b anticorps |
| pl-PL | Polish (Poland) | Interferon.beta 1b Ab Synonyms: Przeciwciała do interferonu beta 1b |
LOINC Copyright
Copyright © Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://